Skip to main content
Publications
van Kamp I, Waye KP, Kanninen K, Gulliver J, Bozzon A, Psyllidis A, Boshuizen H, Selander J, van den Hazel P, Brambilla M, Foraster M , Julvez J, Klatte M, Jeram S, Lercher P, Botteldooren D, Ristovska G, Kaprio J, Schreckenberg D, Hornikx M, Fels J, Weber M, Braat-Eggen E, Hartmann J, Clark C, Vrijkotte T, Brown L, Bolte G. Early environmental quality and life-course mental health effects: the equal-life project . Environ Epidemiol. 2021 Dec 16;6(1):e183. doi: 10.1097/EE9.0000000000000183
Wesselink AK, Kirwa K, Hatch EE, Hystad P, Szpiro AA, Kaufman JD, Levy JI, Mikkelsen EM, Quraishi SM, Rothman KJ , Wise LA. Residential proximity to major roads and fecundability in a preconception cohort . Environ Epidemiol. 2020 Nov 11;4(6):e112. doi: 10.1097/EE9.0000000000000112
Phiri K, Hallas J, Linder M, Margulia A , Suehs B, Arana A , Bahmanyar S, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S , Sahlertz Kristiansen N, Appenteng K, de Vogel S, Seeger J. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder . Poster presented at the American Urological Association 2020 Conference (Conference cancelled); May 2020. Washington, DC. [abstract] J Urol. 2020 Apr; 203(Supplement 4):e910-1. doi: 10.1097/JU.0000000000000931.010
Boccia S, Rothman KJ , Panic N, Flacco ME, Rosso A, Pastorino R, Manzoli L, La Vecchia C, Villari P, Boffetta P, Ricciardi W, Ioannidis JP. Registration practices for observational studies on ClinicalTrials.gov indicated low adherence . J Clin Epidemiol. 2016 Feb;70:176-82. doi: 10.1016/j.jclinepi.2015.09.009
Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas JG, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X , Maurel J. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study . Invest New Drugs. 2013 Dec;31(6):1573-9.